Skip to main content
PMC home page
British Medical Journal logoLink to British Medical Journal
. 1970 Jun 6;2(5709):568–570. doi: 10.1136/bmj.2.5709.568

Clinical and Metabolic Study in Diabetic Patients Treated with Glibenclamide

J Anderson, R Coulson, B D M Grassick, B A Morris, W D Thomas, R W S Tomlinson, F Woodroffe
PMCID: PMC1700241  PMID: 5526611

Abstract

A clinical and metabolic study of 32 patients treated with glibenclamide for a period of about one year confirmed that the drug is a potent stimulator of insulin release in maturity onset diabetes, and glibenclamide continued to have this action after a period of eight months. The drug is effective in doses as low as 2·5 mg., and the maximum effective dose is about 15 mg. No significant side-effects were found during the period of the study, in particular there was no alcohol flushing. The metabolic investigations have shown that the drug has some actions which are as yet unexplained.

Full text

PDF
568

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aumüller W., Bänder A., Heerdt R., Muth K., Pfaff W., Schmidt F. H., Weber H., Weyer R. Ein neues hochwirksames orales Antidiabeticum. Arzneimittelforschung. 1966 Dec;16(12):1640–1641. [PubMed] [Google Scholar]
  2. Chu P. C., Conway M. J., Krouse H. A., Goodner C. J. The pattern of rsponse of plasma insulin and glucose to meals and fasting during chlorpropamide therapy. Ann Intern Med. 1968 Apr;68(4):757–769. doi: 10.7326/0003-4819-68-4-757. [DOI] [PubMed] [Google Scholar]
  3. DOLE V. P. A relation between non-esterified fatty acids in plasma and the metabolism of glucose. J Clin Invest. 1956 Feb;35(2):150–154. doi: 10.1172/JCI103259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. DUNCAN L. J., BAIRD J. D. Compounds administered orally in the treatment of diabetes mellitus. Pharmacol Rev. 1960 Mar;12:91–158. [PubMed] [Google Scholar]
  5. FITZGERALD M. G., GADDIE R., MALINS J. M., O'SULLIVANDJ Alcohol sensitivity in diabetics receiving chlorpropromide. Diabetes. 1962 Jan-Feb;11:40–43. [PubMed] [Google Scholar]
  6. HALES C. N., RANDLE P. J. Immunoassay of insulin with insulin-antibody precipitate. Biochem J. 1963 Jul;88:137–146. doi: 10.1042/bj0880137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. SCHRADE W., BOEHLE E., BIEGLER R., HARMUTH E. Fatty-acid composition of lipid fractions in diabetic serum. Lancet. 1963 Feb 9;1(7276):285–290. doi: 10.1016/s0140-6736(63)92236-0. [DOI] [PubMed] [Google Scholar]
  8. Seltzer H. S., Allen E. W., Herron A. L., Jr, Brennan M. T. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest. 1967 Mar;46(3):323–335. doi: 10.1172/JCI105534. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Sheldon J., Taylor K. W., Anderson J. The effects of long-term acetohexamide treatment on pancreatic islet cell function in maturity-onset diabetes. Metabolism. 1966 Oct;15(10):874–883. doi: 10.1016/0026-0495(66)90158-2. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES